Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07380412 · ClinicalTrials.gov registry record · NA

A Study to Evaluate the Effects of a Supplement on the Side Effects Associated With Stimulant Medications

A NA study of ADHD and Sleep Disturbance, sponsored by Outliers.

Recruiting
Registry status
NA
Development phase
90
Enrollment target
1
Study location

NCT07380412 is a NA study of ADHD and Sleep Disturbance that is actively recruiting participants, run by Outliers. The registered enrollment target is 90 participants, below the 189-participant average among 75 other ADHD trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07380412, a NA study of ADHD and Sleep Disturbance, is actively recruiting participants, sponsored by Outliers.

RECRUITING
Registry status
NA
Development phase
90 participants
Enrollment target
1
Study location

Study Summary

This is a hybrid, two-arm, triple-blind, placebo-controlled, randomized clinical trial evaluating the efficacy of the Stasis supplement on reducing oxidative stress, cortisol levels, and side effects associated with stimulant medications used for ADHD over a three-month period in adults.

Interventions

  • DIETARY_SUPPLEMENT Placebo
  • DIETARY_SUPPLEMENT Stasis Daytime and Nighttime

Study Locations (1)

Nevada

  • Citruslabs - Las Vegas

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2025-08-12
Est. Completion 2026-03
Phase NA

Sponsor

Outliers

1 total trials

What the Registry Record Tells You About NCT07380412

The ClinicalTrials.gov registry entry for NCT07380412 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 189-participant average among 75 other ADHD trials with a reported enrollment target (52% lower). The listed sponsor is Outliers, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with ADHD appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07380412 reports 1 study location spanning 1 distinct geographic area - top geographies include Nevada.

Frequently Asked Questions

What is clinical trial NCT07380412 about?

NCT07380412 is a clinical study titled "A Study to Evaluate the Effects of a Supplement on the Side Effects Associated With Stimulant Medications". This is a hybrid, two-arm, triple-blind, placebo-controlled, randomized clinical trial evaluating the efficacy of the Stasis supplement on reducing oxidative stress, cortisol levels, and side effects associated with stimulant medications used for ADHD over a three-month period in adults.

What is the current status of trial NCT07380412?

This trial is currently recruiting. It is a NA study. The enrollment target is 90 participants. The study started on 2025-08-12. Estimated completion is 2026-03.

What conditions does trial NCT07380412 study?

This clinical trial studies the following conditions: ADHD, Sleep Disturbance, Brain Fog.

What interventions are being tested in trial NCT07380412?

The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Stasis Daytime and Nighttime (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT07380412?

This trial is sponsored by Outliers, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07380412 being conducted?

This trial has 1 study location across Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for ADHD

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.